Holen Sie sich die Stockscreener-App
0.2397
15.98%
-0.0456
Handel nachbörslich:
.23
-0.0097
-4.05%
Schlusskurs vom Vortag:
$0.2853
Offen:
$0.27
24-Stunden-Volumen:
40.22M
Relative Volume:
0.66
Marktkapitalisierung:
$37.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+22.30%
1M Leistung:
+180.02%
6M Leistung:
-78.21%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.22
$0.27
1-Wochen-Bereich:
$0.1714
$0.4477
52-Wochen-Spanne:
$0.0636
$10.95
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Firmenname
Cero Therapeutics Holdings Inc
Sektor
Branche
Telefon
650-407-2376
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Vergleichen Sie CERO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CERO | 0.2397 | 37.08M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cero Therapeutics Holdings Inc Aktie (CERO) Neueste Nachrichten
Selling Your CERo Therapeutics Holdings Inc (CERO) Stock? Here’s What You Need To Know - Stocks Register
FDA clears CERo's new AML drug for phase 1 trials - Investing.com
FDA clears CERo's new AML drug for phase 1 trials By Investing.com - Investing.com UK
CERo Therapeutics, Inc. Receives FDA Clearance of - GlobeNewswire
CERo Therapeutics Secures FDA Clearance for Novel AML Treatment Clinical Trial | CERO Stock News - StockTitan
Cero Therapeutics holdings sees $325,000 stock sale by YK Bioventures - Investing.com UK
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
CERo Therapeutics Holdings, Inc. (CERO): 173% Stock Surge Driven by Promising Preclinical Data for Lead Compound CER-1236 - BP Journal
Crude Oil Down 3%; Aramark Posts Upbeat Earnings - Benzinga
Nasdaq Moves Lower; Canaan Shares Surge - Benzinga
U.S. Stock market: Binah Capital Group(+105.01%) and CERo Therapeutics(+152.00%) see strong gains, RAPT Therapeutics(−44.12%) declines during mid day trading - Business Upturn
U.S. Stock market: RAPT Therapeutics drops 41% while CERo Therapeutics surges 136% in early trading - Business Upturn
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results - Benzinga
CERo Therapeutics, Inc. Presents Preclinical Data - GlobeNewswire
CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan
CEROCERo Therapeutics Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Cero Therapeutics faces NASDAQ delisting - Investing.com India
Cero Therapeutics faces NASDAQ delisting By Investing.com - Investing.com UK
Cero Therapeutics Faces NASDAQ Delisting Over Low Stock Price - Investing.com India
Cero Therapeutics Faces NASDAQ Delisting Over Low Stock Price By Investing.com - Investing.com UK
CERo Therapeutics updates on clinical hold and management changes - Investing.com India
CERo Therapeutics updates on clinical hold and management changes By Investing.com - Investing.com South Africa
CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter - Marketscreener.com
CERo Therapeutics, Inc. Provides Corporate Update - The Bakersfield Californian
CERO’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Are Investors Inclined To Sell Their CERo Therapeutics Holdings Inc. (NASDAQ: CERO) Holdings? - Stocks Register
A closer look at CERO’s price-to-free cash flow ratio - US Post News
CERo Therapeutics Holdings Inc.’s Market Journey: Closing Strong at 0.10, Up 0.63 - The Dwinnex
Take off with CERo Therapeutics Holdings Inc. (CERO): Get ready for trading - SETE News
Cero Therapeutics announces financial update and board changes - Investing.com India
Cero Therapeutics announces financial update and board changes By Investing.com - Investing.com South Africa
An analyst sees good growth prospects for CERo Therapeutics Holdings Inc. (CERO) - SETE News
CERo Therapeutics Holdings Inc. Inc. (CERO) Price Performance: The Role of Volume and Liquidity - The InvestChronicle
CERo Therapeutics Holdings Inc. (CERO) deserves closer scrutiny - US Post News
Trading Day Review: CERo Therapeutics Holdings Inc. (CERO) Gains Momentum, Closing at 0.09 - The Dwinnex
CERo Therapeutics appoints new CFO and CDO - Investing.com India
CERo Therapeutics appoints new CFO and CDO By Investing.com - Investing.com Canada
CERo Therapeutics Enhances Leadership for Clinical Advancements - TipRanks
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer - ForexTV.com
CERo Therapeutics Holdings, Inc. Appoints Kristen Pierce as Chief Development Officer - Marketscreener.com
A Look at CERo Therapeutics Holdings Inc. (CERO) Shares in the Recent Past Indicates Growth - SETE News
Market cap of CERo Therapeutics Holdings Inc. [CERO] reaches 4.79M – now what? - The DBT News
CERo Therapeutics Holdings Inc. (CERO)’s stock price range in the last year - US Post News
Financial Fitness Check: Examining CERo Therapeutics Holdings Inc. (CERO)’s Key Ratios - The Dwinnex
Cero Therapeutics cancels special stockholder meeting By Investing.com - Investing.com Australia
Cero Therapeutics cancels special stockholder meeting - Investing.com
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
CERo Therapeutics seeks FDA meeting, reshuffles leadershi By Investing.com - Investing.com Australia
CERo Therapeutics says CEO Atwood, CFO Carter to step down - MSN
CERo Therapeutics’ Strategic Moves Amidst Leadership Change - TipRanks
Finanzdaten der Cero Therapeutics Holdings Inc-Aktie (CERO)
Es liegen keine Finanzdaten für Cero Therapeutics Holdings Inc (CERO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):